BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19474457)

  • 1. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
    Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Björkhem-Bergman L; Lütjohann D; Björkhem I; Pikuleva IA
    J Lipid Res; 2010 Feb; 51(2):318-23. PubMed ID: 19474457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo consequences of cholesterol-24S-hydroxylase (CYP46A1) inhibition by voriconazole on cholesterol homeostasis and function in the rat retina.
    Fourgeux C; Martine L; Acar N; Bron AM; Creuzot-Garcher CP; Bretillon L
    Biochem Biophys Res Commun; 2014 Apr; 446(3):775-81. PubMed ID: 24491555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.
    Mast N; Charvet C; Pikuleva IA; Stout CD
    J Biol Chem; 2010 Oct; 285(41):31783-95. PubMed ID: 20667828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.
    Mast N; Zheng W; Stout CD; Pikuleva IA
    Mol Pharmacol; 2013 Jul; 84(1):86-94. PubMed ID: 23604141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24S-hydroxycholesterol and cholesterol-24S-hydroxylase (CYP46A1) in the retina: from cholesterol homeostasis to pathophysiology of glaucoma.
    Fourgeux C; Bron A; Acar N; Creuzot-Garcher C; Bretillon L
    Chem Phys Lipids; 2011 Sep; 164(6):496-9. PubMed ID: 21531213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.
    Mast N; White MA; Bjorkhem I; Johnson EF; Stout CD; Pikuleva IA
    Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9546-51. PubMed ID: 18621681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol-24S-hydroxylase (CYP46A1) is specifically expressed in neurons of the neural retina.
    Bretillon L; Diczfalusy U; Björkhem I; Maire MA; Martine L; Joffre C; Acar N; Bron A; Creuzot-Garcher C
    Curr Eye Res; 2007 Apr; 32(4):361-6. PubMed ID: 17453958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxysterols in the brain of the cholesterol 24-hydroxylase knockout mouse.
    Meljon A; Wang Y; Griffiths WJ
    Biochem Biophys Res Commun; 2014 Apr; 446(3):768-74. PubMed ID: 24491562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury.
    Cartagena CM; Burns MP; Rebeck GW
    Brain Res; 2010 Mar; 1319():1-12. PubMed ID: 20053345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease.
    Djelti F; Braudeau J; Hudry E; Dhenain M; Varin J; Bièche I; Marquer C; Chali F; Ayciriex S; Auzeil N; Alves S; Langui D; Potier MC; Laprevote O; Vidaud M; Duyckaerts C; Miles R; Aubourg P; Cartier N
    Brain; 2015 Aug; 138(Pt 8):2383-98. PubMed ID: 26141492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.
    Mast N; Linger M; Clark M; Wiseman J; Stout CD; Pikuleva IA
    Mol Pharmacol; 2012 Nov; 82(5):824-34. PubMed ID: 22859721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription of cytochrome P450 46A1 in NIH3T3 cells is negatively regulated by FBS.
    Shinohara Y; Ando H; Maekawa M; Arai M; Horibata Y; Satou M; Jojima T; Usui I; Aso Y; Sugimoto H
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jun; 1867(6):159136. PubMed ID: 35306146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes.
    Ohyama Y; Meaney S; Heverin M; Ekström L; Brafman A; Shafir M; Andersson U; Olin M; Eggertsen G; Diczfalusy U; Feinstein E; Björkhem I
    J Biol Chem; 2006 Feb; 281(7):3810-20. PubMed ID: 16321981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol 24S-Hydroxylase Overexpression Inhibits the Liver X Receptor (LXR) Pathway by Activating Small Guanosine Triphosphate-Binding Proteins (sGTPases) in Neuronal Cells.
    Moutinho M; Nunes MJ; Gomes AQ; Gama MJ; Cedazo-Minguez A; Rodrigues CM; Björkhem I; Rodrigues E
    Mol Neurobiol; 2015; 51(3):1489-503. PubMed ID: 25084760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol metabolism in the brain: importance of 24S-hydroxylation.
    Lütjohann D
    Acta Neurol Scand Suppl; 2006; 185():33-42. PubMed ID: 16866909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology.
    Burlot MA; Braudeau J; Michaelsen-Preusse K; Potier B; Ayciriex S; Varin J; Gautier B; Djelti F; Audrain M; Dauphinot L; Fernandez-Gomez FJ; Caillierez R; Laprévote O; Bièche I; Auzeil N; Potier MC; Dutar P; Korte M; Buée L; Blum D; Cartier N
    Hum Mol Genet; 2015 Nov; 24(21):5965-76. PubMed ID: 26358780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.
    Kölsch H; Lütjohann D; Jessen F; Popp J; Hentschel F; Kelemen P; Schmitz S; Maier W; Heun R
    Eur Psychiatry; 2009 Apr; 24(3):183-90. PubMed ID: 19286353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain.
    Mast N; Norcross R; Andersson U; Shou M; Nakayama K; Bjorkhem I; Pikuleva IA
    Biochemistry; 2003 Dec; 42(48):14284-92. PubMed ID: 14640697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary open-angle glaucoma: association with cholesterol 24S-hydroxylase (CYP46A1) gene polymorphism and plasma 24-hydroxycholesterol levels.
    Fourgeux C; Martine L; Björkhem I; Diczfalusy U; Joffre C; Acar N; Creuzot-Garcher C; Bron A; Bretillon L
    Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5712-7. PubMed ID: 19553612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
    Vega GL; Weiner MF; Lipton AM; Von Bergmann K; Lutjohann D; Moore C; Svetlik D
    Arch Neurol; 2003 Apr; 60(4):510-5. PubMed ID: 12707064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.